Core Insights - Shanghai Pharmaceuticals reported a revenue of 215,072,230,363.46 yuan for the first three quarters of 2025, representing a year-on-year growth of 2.60% [2] - The net profit attributable to shareholders of the listed company reached 5,147,064,933.11 yuan, showing a significant year-on-year increase of 26.96% [2] Financial Performance - Revenue for the first three quarters of 2025: 215.07 billion yuan, up 2.60% year-on-year [2] - Net profit for the same period: 5.15 billion yuan, up 26.96% year-on-year [2]

Core Insights - Shanghai Pharmaceuticals reported a revenue of 215.07 billion yuan for the first nine months of 2025, a year-on-year increase of 2.60%, with pharmaceutical manufacturing sales at 18.16 billion yuan and pharmaceutical commerce sales at 196.91 billion yuan, up 2.91% year-on-year [1] - The company achieved a net profit attributable to shareholders of 5.15 billion yuan, reflecting a significant year-on-year growth of 26.96% [1] R&D Investment and Pipeline Progress - The company maintained a high level of R&D investment at 1.73 billion yuan, accounting for 9.52% of pharmaceutical manufacturing sales, with R&D expenses at 1.51 billion yuan [2] - As of the reporting period, the company had 57 new drug pipelines accepted for clinical trials, including 45 innovative drugs [2] - Notable advancements include the NDA submission for BCD-085, a monoclonal antibody for ankylosing spondylitis, and the completion of patient enrollment for the Phase III trial of a traditional Chinese medicine for cervical spondylotic myelopathy [2] Traditional Chinese Medicine Business - The traditional Chinese medicine segment achieved breakthroughs through "innovation while maintaining integrity," with key clinical studies completed for several core products [3] - The company successfully exported its traditional Chinese medicine products to Canada, marking a significant step in internationalization [3] Rare Disease Initiatives - The company views rare disease treatment as a key aspect of its corporate social responsibility, focusing on R&D, supply chain, and ecosystem development [4] - A dedicated rare disease R&D team has been established, with multiple pipelines under development, including SRD4610 for amyotrophic lateral sclerosis [4] - The company has 51 products for rare diseases, covering 67 different rare disease conditions [4] Pharmaceutical Commerce Growth - The pharmaceutical commerce segment continued to grow through innovation, with strategic partnerships with companies like Baxter China and others [5] - The innovative drug business saw sales revenue of 40.7 billion yuan, a year-on-year increase of over 25%, while the import agency business generated 27.6 billion yuan, up over 14% [5] New Retail Strategy and Digital Transformation - The company is advancing its new retail strategy focused on "hospital-side pharmacies + DTP specialty pharmacies," leveraging AI to enhance traditional business operations [6] - The digital upgrade of pharmaceutical services through Shenyang Health aims to provide comprehensive health management services for patients [6]

Core Insights - Shanghai Pharmaceuticals reported a revenue of 215.07 billion RMB for the first three quarters of 2025, marking a year-on-year growth of 2.60% [1] - The company achieved a net profit attributable to shareholders of 5.15 billion RMB, reflecting a significant year-on-year increase of 26.96% [1] Financial Performance - Revenue breakdown: Pharmaceutical manufacturing sales reached 18.16 billion RMB, while pharmaceutical commerce sales were 196.91 billion RMB, with the latter growing by 2.91% year-on-year [1] - Operating cash flow for the period was 2.35 billion RMB, indicating sustained high-quality development [1] R&D Investment - R&D investment totaled 1.73 billion RMB, accounting for 9.52% of pharmaceutical manufacturing sales, with 1.51 billion RMB specifically allocated for R&D expenses [2] - The company has 57 new drug applications in the pipeline, including 45 innovative drugs, with significant progress in clinical trials for several key products [2] Traditional Chinese Medicine (TCM) Business - The TCM segment achieved breakthroughs through evidence-based research and international standardization efforts [3] - New product launches and branding initiatives targeted at younger consumers were implemented, enhancing the company's market presence [3] - Successful export of TCM products to Canada, including the first TCM compound preparation to enter the Canadian market under a Western medicine indication [3] Rare Disease Initiatives - The company is committed to addressing rare diseases through R&D, supply chain optimization, and ecosystem building [4] - A dedicated rare disease R&D team has been established, with multiple drug candidates in various stages of clinical trials [4] - Collaboration with stakeholders to create a comprehensive ecosystem for rare disease prevention and treatment has been initiated [4] Commercial Innovation and Growth - The pharmaceutical commercial segment continued to grow through innovation, strategic partnerships, and digital transformation [6] - Sales from innovative drug products reached 40.7 billion RMB, with a year-on-year growth exceeding 25% [6] - The company is advancing a new retail strategy focused on specialized pharmacies and leveraging AI for traditional business enhancement [6]

智通财经APP讯，上海医药(02607)发布2025年第三季度报告，2025年1-9月，公司实现营业收入2150.72 亿元(币种为人民币，下同)，同比增长2.60%。其中：医药工业实现销售收入181.64亿元，同比下降 0.66%;医药商业实现销售收入1969.08亿元，同比增长2.91%。公司实现归属于上市公司股东的净利润 51.47亿元(其中：工业板块贡献利润16.65亿元，商业板块贡献利润26.53亿元，主要参股企业贡献利润 3.24亿元)，同比增长26.96%，主要是由于对和黄药业会计核算由合营企业权益法核算变更为按子公司 核算而产生一次性特殊收益所致，扣除上述事项等一次性特殊损益后的归母净利润为39.79亿元，同比 下降1.85%。公司经营性现金流净流入23.50亿元，持续保持高质量发展。 ...

Core Viewpoint - Shanghai Pharmaceuticals reported a revenue of 215.072 billion RMB for the first nine months of 2025, reflecting a year-on-year growth of 2.60% [1] Revenue Breakdown - The pharmaceutical manufacturing segment generated sales of 18.164 billion RMB, showing a decline of 0.66% year-on-year [1] - The pharmaceutical distribution segment achieved sales of 196.908 billion RMB, with a year-on-year increase of 2.91% [1] Profit Analysis - The net profit attributable to shareholders for the first nine months of 2025 was 5.147 billion RMB, representing a year-on-year increase of 26.96% [1] - The profit contributions were 1.665 billion RMB from the industrial segment, 2.653 billion RMB from the commercial segment, and 0.324 billion RMB from major associated enterprises [1] - Excluding one-time special gains from accounting changes, the adjusted net profit was 3.979 billion RMB, reflecting a year-on-year decrease of 1.85% [1] Cash Flow and Development - The company maintained a strong operational cash flow with a net inflow of 2.350 billion RMB, indicating high-quality development [1] Industry Recognition - Shanghai Pharmaceuticals ranked among the top ten in the "2024 Annual Top 100 Pharmaceutical Industrial Enterprises by Main Business Revenue" in China [1] - The company achieved an upgrade in its MSCI ESG rating to AA, reflecting its strong performance in environmental, social, and governance aspects [1]

Core Insights - Shanghai Pharmaceuticals reported a revenue of 215.072 billion RMB for the first nine months of 2025, representing a year-on-year growth of 2.60% [1] - The pharmaceutical manufacturing segment generated sales of 18.164 billion RMB, showing a decline of 0.66%, while the pharmaceutical distribution segment achieved sales of 196.908 billion RMB, with a growth of 2.91% [1] - The net profit attributable to shareholders for the same period was 5.147 billion RMB, a year-on-year increase of 26.96%, primarily due to a one-time special gain from changing the accounting treatment of a joint venture to a subsidiary [1] - Excluding one-time special gains, the adjusted net profit was 3.979 billion RMB, reflecting a decline of 1.85% year-on-year [1] - The company maintained a strong operating cash flow with a net inflow of 2.350 billion RMB, indicating high-quality development [1] - Shanghai Pharmaceuticals ranked among the top ten in the "2024 Annual Top 100 Pharmaceutical Industrial Enterprises by Main Business Revenue" and achieved an upgrade to AA rating in MSCI ESG ratings due to its strong ESG performance [1]

格隆汇10月30日丨上海医药(02607.HK)公告，于2025年10月30日，公司与永发印务订立期限自2026年1 月1日起至2026年12月31日止为期一年的采购框架协议，据此，永发印务集团将向集团继续提供药品的 印刷包装材料。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 2025年第三季度報告 本公告乃根據證券及期貨條例（香港法例第571章）第XIVA部及香港聯合交易所有限公司 證券上市規則第13.09條而發表。 以下為上海醫藥集團股份有限公司2025年第三季度報告，其所載財務報告根據中國企業 會計準則編製，並且未經審計。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，二零二五年十月三十一日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先生； 非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生、王忠先生 及萬鈞女士。 * 僅供識別 - 1 - 本公司董事會及全體董事保證本公告內容不存在任何虛假記載、誤導性陳述或者重大遺 漏，並對 ...

交易概述：2025 年 10 月 30 日， 上海医药集团股份有限公司（以下简 称"公司""本公司"或"本集团"）与关联方永发印务有限公司（以下简称 "永发印务"或"永发印务集团"）续签《采购框架协议》（以下简称"框架协 议"）。根据框架协议，自 2026 年 1 月 1 日起至 2026 年 12 月 31 日止，本公司（根 据《香港联合交易所有限公司证券上市规则》定义，包括公司现已成立及将来可 能成立之附属公司及其 30%受控公司）向永发印务（包括永发印务已成立及将来 可能成立之附属公司）采购药品印刷包装材料，采购金额年度上限为人民币 9,000 万元（以下简称"本次交易"）。 根据《上海证券交易所股票上市规则》（以下简称"《上交所上市规则》"）， 框架协议项下的日常关联交易的最高年度上限占本公司最近一期经审计净资产 绝对值低于0.5%，无需进行披露；本次公告的刊发是根据《香港联合交易所有限 公司证券上市规则》（以下简称"《联交所上市规则》"）第14A.07条，框架协议项 下的日常关联交易的最高年度上限适用百分比率超过0.1%但低于5%，仅须遵守 申报、年度审核及公告要求，豁免遵守通函及独立股东批准要求。 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司第八屆董事會第二十五次會議決議公告》、《上海醫藥集 團股份有限公司第八屆監事會第十四次會議決議公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 中國上海，2025 年 10 月 31 日 ...